- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07939620
Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity
Double-blind, Randomized, Non-inferiority Clinical Study to Evaluate the Efficacy of a Toothpaste Containing 20% Hydroxyapatite (HAP) and 2% Calcium Hypophosphite (CaP) Compared With Two Comparator Toothpastes by Assessing the Impact on Symptoms of Dentin Hypersensitivity Over a Study Duration of 56 Days (8 Weeks), as Well as Its Safety and Tolerability in Research Participants With Dentin Hypersensitivity
This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.
A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.
The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.
Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.
Přehled studie
Postavení
Podmínky
Detailní popis
Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Anastasia Harder
- Telefonní číslo: +49521-8808-538
- E-mail: anastasia.harder@drwolffgroup.com
Studijní místa
-
-
Valinhos
-
São Paulo, Valinhos, Brazílie, 13270-180
- Nábor
- Kosmoscience
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Men and women aged between 18 and 65 years.
- Presenting with dentin hypersensitivity.
- At least one eligible tooth (incisor, canine, premolar, or first molar) must have visibly exposed cervical dentin on the facial surface and a score at least 30 mm on the 100-mm VAS immediately after the airblast test (VAS: 0 mm: no sensitivity; 100 mm: worst imaginable sensitivity)
- Proper periodontal health (i.e. no probing depth > 4 mm, or other conditions that might explain their apparent dentin hypersensitivity
- To be in good general health, as assessed by the investigator.
Exclusion Criteria:
- Previous professional desensitizing treatment within the past 3 months (e.g., in-office fluoride varnish, laser desensitization)
- Use of over-the-counter desensitizing products within the previous 8 weeks
- Medical histories made remarkable by chronic use of antibiotics, anti-inflammatory, analgesic, anticonvulsant, sedative, and psychotropic drugs; or ongoing active treatment with any of these drug classes at the time of screening
- Pregnancy and breastfeeding
- Allergies and idiosyncratic responses to product ingredients (e.g., any ingredient of the investigational or comparator products)
- Teeth or periodontium with pathology or defects likely to cause pain (e.g., periodontal abscess, tooth mobility greater than Grade 1) (applies to teeth designated for sensitivity assessment)
Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: 20% Hydroxyapatite and 2% Calcium Hypophosphite Toothpaste
|
Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
|
Aktivní komparátor: Stannous Fluoride Toothpaste
|
Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
|
Aktivní komparátor: 8% Arginine Toothpaste
|
Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56
Časové okno: Baseline (Day 1) to Day 56 (±3 Days)
|
The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm). |
Baseline (Day 1) to Day 56 (±3 Days)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean change in VAS (Cold Water Test) from Baseline to Day 56
Časové okno: Baseline (Day 1) to Day 56 (±3 Days)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 56 (±3 Days)
|
|
Mean change in VAS (Airblast test) from Baseline to Day 28
Časové okno: Baseline (Day 1) to Day 28 (±3 Days)
|
Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 28 (±3 Days)
|
|
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application
Časové okno: Day 1 (Baseline and directly after the first application)
|
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Day 1 (Baseline and directly after the first application)
|
|
Mean change in VAS (Cold Water test) from Baseline to Day 28
Časové okno: Baseline (Day 1) to Day 28 (±3 Days)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 28 (±3 Days)
|
|
Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application
Časové okno: Day 1 (Baseline and directly after the first application)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Day 1 (Baseline and directly after the first application)
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Ana Lúcia Tabarini Alves Pinheiro, MD, Kosmoscience Ciência e Tecnologia Cosmética, Importação e Exportação Ltda.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- DH-03/2025
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
All data and information retrieved within the investigation are an intellectual property of the Sponsor.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .